STEMRIM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 457 JPY | -2.35% |
|
-2.77% | -20.93% |
| 05-09 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| 03-13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 185M | - | - | - | |||
| 92.59B | ||||||
| 41.43B | ||||||
| 33.49B | ||||||
| 14.62B | ||||||
| 12.77B |
- Stock Market
- Equities
- 4599 Stock
- Charts StemRIM
- Sector Chart
